Detection and molecular genetics of extended-spectrum beta-lactamases among cefuroxime-resistant Escherichia coli and Klebsiella spp. isolates from Finland, 2002–2004

References

• Clinical and Laboratory Standards Institute (2005). Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Sixth edition. Approved Standard. M7-A6, Wayne, PAUSA.
   Google Scholar
• Datta N, Kontomichalou P. Penicillinase synthesis controlled by infectious R factors in Enterobacteriaceae. Nature 1965; 208: 239–41
   PubMed Web of Science ®Google Scholar
• Kliebe C, Nies BA, Meyer JF, Tolxdorff-Neutzling RM, Wiedemann B. Evolution of plasmid-coded resistance to broad-spectrum cephalosporins. Antimicrob Agents Chemother 1985; 28: 302–7
   PubMed Web of Science ®Google Scholar
• Matsumoto Y, Ikeda F, Kamimura T, Yokota Y, Mine Y. Novel plasmid-mediated beta-lactamase from Escherichia coli that inactivates oxyimino-cephalosporins. Antimicrob Agents Chemother 1988; 32: 1243–6
   PubMed Web of Science ®Google Scholar
• Bauernfeind A, Stemplinger I, Jungwirth R, Ernst S, Casellas J. Sequences of beta-lactamase genes encoding CTX-M-1 (MEN-1) and CTX-M-2 and relationship of their amino acid sequences with those of other β-lactamases. Antimicrob Agents Chemother 1996; 40: 509–13
   PubMed Web of Science ®Google Scholar
• Alobwede I, M'Zali FH, Livermore DM, Heritage J, Todd N, Hawkey PM. CTX-M extended-spectrum beta-lactamase arrives in the UK. J Antimicrob Chemother 2003; 51: 470–1
   PubMed Web of Science ®Google Scholar
• Fang H, Lundberg C, Olsson-Liljequist B, Hedin G, Lindback E, Rosenberg A, et al. Molecular epidemiological analysis of Escherichia coli isolates producing extended-spectrum β-lactamases for identification of nosocomial outbreaks in Stockholm, Sweden. J Clin Microbiol 2004; 42: 5917–20
   PubMed Web of Science ®Google Scholar
• Bonnet R. Growing group of extended-spectrum β-lactamases: the CTX-M enzymes. Antimicrob Agents Chemother 2004; 48: 1–14
   PubMed Web of Science ®Google Scholar
• Eckert C, Gautier V, Saladin-Allard M, Hidri N, Verdet C, Ould-Hocine Z, et al. Dissemination of CTX-M-type β-lactamases among clinical isolates of Enterobacteriaceae in Paris, France. Antimicrob Agents Chemother 2004; 48: 1249–55
   PubMed Web of Science ®Google Scholar
• Moland ES, Black JA, Hossain A, Hanson ND, Thomson KS, Pottumarthy S. Discovery of CTX-M-like extended-spectrum β-lactamases in Escherichia coli isolates from 5 US States. Antimicrob Agents Chemother 2003; 47: 2382–3
   PubMed Web of Science ®Google Scholar
• Cormican M, Marshall S, Jones R. Detection of extended-spectrum β-lactamase (ESBL)-producing strains by the E-test ESBL screen. J Clin Microbiol 1996; 34: 1880–4
   PubMed Web of Science ®Google Scholar
• Sanders CC, Barry AL, Washington JA, Shubert C, Moland ES. Traczewski MM, et al. Detection of extended-spectrum beta-lactamase-producing members of the family Enterobacteriaceae with Vitek ESBL test. J Clin Microbiol 1996; 34: 2997–3001
   PubMed Web of Science ®Google Scholar
• Manninen, R, Auvinen, H, Huovinen, P, the Finnish Study Group for Antimicrobial Resistance. Resistance to second- and third-generation cephalosporins among Escherichia coli and Klebsiella species is rare in Finland. Clin Microbiol Infect 1997;3:408–13.
   PubMedGoogle Scholar
• Cao V, Lambert T, Nhu DQ, Loan HK, Hoang NK, Arlet G, et al. Distribution of extended-spectrum beta-lactamases in clinical isolates of Enterobacteriaceae in Vietnam. Antimicrob Agents Chemother 2002; 46: 3739–43
   PubMed Web of Science ®Google Scholar
• Eckert C, Gautier V, Saladin-Allard M, Hidri N, Verdet C, Ould-Hocine Z, et al. Dissemination of CTX-M-type beta-lactamases among clinical isolates of Enterobacteriaceae in Paris, France. Antimicrob Agents Chemother 2004; 48: 1249–55
   PubMed Web of Science ®Google Scholar
• Tofteland, S, Haldorsen, B, Dahl, KH, Simonsen, GS, Steinbakk, M, Walsh, TR, , et al. CTX-M is the dominating extended-spectrum beta-lactamase (ESBL)-type in Norwegian clinical isolates of Escherichia coli and Klebsiella pneumoniae. 2004, Poster ECCMID Prague May 2004.
   Google Scholar
• Szabo D, Melan MA, Hujer AM, Bonomo RA, Hujer KM, Bethel CR, et al. Molecular analysis of the simultaneous production of 2 SHV-type extended-spectrum beta-lactamases in a clinical isolate of Enterobacter cloacae by using single-nucleotide polymorphism genotyping. Antimicrob Agents Chemother 2005; 49: 4716–20
   PubMed Web of Science ®Google Scholar
• Martinez-Martinez L, Conejo MC, Pascual A, Hernandez-Alles S, Ballesta S, Ramirez De Arellano-Ramos E, et al. Activities of imipenem and cephalosporins against clonally related strains of Escherichia coli hyperproducing chromosomal beta-lactamase and showing altered porin profiles. Antimicrob Agents Chemother 2000; 44: 2534–6
   PubMed Web of Science ®Google Scholar
• Martinez-Martinez L, Hernandez-Alles S, Alberti S, Tomas JM, Benedi VJ, Jacoby GA. In vivo selection of porin-deficient mutants of Klebsiella pneumoniae with increased resistance to cefoxitin and expanded-spectrum cephalosporins. Antimicrob Agents Chemother 1996; 40: 342–8
   PubMed Web of Science ®Google Scholar
• Rice LB, Carias LL, Hujer AM, Bonafede M, Hutton R, Hoyen C, et al. High-level expression of chromosomally encoded SHV-1 beta-lactamase and an outer membrane protein change confer resistance to ceftazidime and piperacillin-tazobactam in a clinical isolate of Klebsiella pneumoniae. Antimicrob Agents Chemother 2000; 44: 362–7
   PubMed Web of Science ®Google Scholar
• Wu TL, Siu LK, Su LH, Lauderdale TL, Lin FM, Leu HS, et al. Outer membrane protein change combined with coexisting TEM-1 and SHV-1 β-lactamases leads to false identification of ESBL-producing Klebsiella pneumoniae. J Antimicrob Chemother 2001; 47: 755–61
   PubMed Web of Science ®Google Scholar
• Miro E, del Cuerpo M, Navarro F, Sabate M, Mirelis B, Prats G. Emergence of clinical Escherichia coli isolates with decreased susceptibility to ceftazidime and synergic effect with co-amoxiclav due to SHV-1 hyperproduction. J Antimicrob Chemother 1998; 42: 535–8
   PubMed Web of Science ®Google Scholar
• Steward CD, Rasheed JK, Hubert SK, Biddle JW, Raney PM, Anderson GJ, et al. Characterization of clinical isolates of Klebsiella pneumoniae from 19 laboratories using the National Committee for Clinical Laboratory Standards extended-spectrum beta-lactamase detection methods. J Clin Microbiol 2001; 39: 2864–72
   PubMed Web of Science ®Google Scholar
• Thomson KS. Controversies about extended-spectrum and AmpC beta-lactamases. Emerg Infect Dis 2001; 7: 333–6
   PubMed Web of Science ®Google Scholar
• Caroff N, Espaze E, Gautreau D, Richet H, Reynaud A. Analysis of the effects of −42 and −32 ampC promoter mutations in clinical isolates of Escherichia coli hyperproducing AmpC. J Antimicrob Chemother 2000; 45: 783–8
   PubMed Web of Science ®Google Scholar
• Gheorghiu R, Yuan M, Hall L, Livermore D. Bases of variation in resistance to β-lactams in Klebsiella oxytoca isolates hyperproducing K1 β-lactamase. J Antimicrob Chemother 1997; 40: 533–41
   PubMed Web of Science ®Google Scholar
• Fournier B, Roy PH. Variability of chromosomally encoded β-lactamases from Klebsiella oxytoca. Antimicrob Agents Chemother 1997; 41: 1641–8
   PubMed Web of Science ®Google Scholar
• Fournier B, Roy P, Lagrange P, Philippon A. Chromosomal beta-lactamase genes of Klebsiella oxytoca are divided into 2 main groups, blaOXY-1 and blaOXY-2. Antimicrob Agents Chemother 1996; 40: 454–9
   PubMed Web of Science ®Google Scholar
• Potz NA, Colman M, Warner M, Reynolds R, Livermore DM. False-positive extended-spectrum beta-lactamase tests for Klebsiella oxytoca strains hyperproducing K1 beta-lactamase. J Antimicrob Chemother 2004; 53: 545–7
   PubMed Web of Science ®Google Scholar